Yazid Arkam

Commercial <scp>anti‐CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Pierre Sesques, Emmanuelle Ferrant, Violaine Safar et al. · American Journal of Hematology · 2020 · 135 citations · Full text

Medicine, Hematology, Oncology +16

Long-term benefit of intracardiac delivery of autologous granulocyte–colony-stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct

Stéphanie Pasquet, H. Sovalat, Philippe Hénon et al. · Cytotherapy · 2009 · 48 citations

Medicine, Cardiology, Cell Biology +17

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma

Rémy Gressin, Nicolas Daguindau, Adrian Tempescul et al. · Haematologica · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

François Guilhot, Françoise Rigal‐Huguet, Joëlle Guilhot et al. · Leukemia · 2021 · 31 citations

Pharmacy, Hematology, Pharmacotherapy +14

Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group

Rémy Gressin, Mary Callanan, Nicolas Daguindau et al. · Blood · 2014 · 22 citations

Medicine, Geriatric Medicine, Oncology +3